{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:55:25Z","timestamp":1791201325869,"version":"4.2.0"},"reference-count":24,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Optimal blood pressure (BP) control remains elusive for millions of patients worldwide, often leading to resistant or secondary hypertension. Overactivation of the mineralocorticoid receptor (MR) drives this systemic pathology. While steroidal mineralocorticoid receptor antagonists (MRAs) are effective, their clinical utility is limited by poor cross-selectivity and risk of hyperkalemia. Finerenone, a novel non-steroidal MRA, offers high selectivity and potent target-organ protection, but a comprehensive pooling of its direct impact on BP is still needed. Methods: Following the PRISMA guidelines, a systematic search was conducted across PubMed, Embase, and ClinicalTrials.gov up to August 2026 for randomized controlled trials (RCTs) comparing finerenone versus placebo and reporting BP outcomes. The primary outcome was office systolic blood pressure (SBP). Results: Six RCTs involving 19,609 patients were included. Finerenone demonstrated a statistically significant but modest reduction in both office SBP (LSM difference: \u22122.83 mmHg; 95% CI: \u22123.15 to \u22122.51; p &lt; 0.001) and office diastolic blood pressure (DBP) (LSM difference: \u22121.04 mmHg; 95% CI: \u22121.37 to \u22120.70; p &lt; 0.001) compared with the placebo, with an absence of statistical heterogeneity (I2 = 0.00%). Subgroup analysis confirmed office SBP-lowering efficacy across different clinical phenotypes, including chronic kidney disease and heart failure (p for interaction = 0.18). In a small subset of patients, finerenone reduced 24-h ambulatory SBP (LSM difference: \u22127.88 mmHg; 95% CI: \u221210.94 to \u22124.82; p &lt; 0.001), though these exploratory findings warrant caution due to the limited sample size; no significant reduction was observed for 24-h ambulatory DBP. Conclusions: Finerenone is associated with a modest but statistically significant reduction in systemic SBP.<\/jats:p>","DOI":"10.3390\/jcm15197694","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:57:46Z","timestamp":1791197866000},"page":"7694","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blood Pressure-Lowering Effects of Finerenone: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-1697","authenticated-orcid":false,"given":"Gaetano","family":"Marino","sequence":"first","affiliation":[{"name":"Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, 00135 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8586-9930","authenticated-orcid":false,"given":"Stefania Angela","family":"Di Fusco","sequence":"additional","affiliation":[{"name":"Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, 00135 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Graziano","sequence":"additional","affiliation":[{"name":"Independent Researcher, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Corradetti","sequence":"additional","affiliation":[{"name":"Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, 00135 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aquilani","sequence":"additional","affiliation":[{"name":"Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, 00135 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8518-0877","authenticated-orcid":false,"given":"Silvio","family":"Fedele","sequence":"additional","affiliation":[{"name":"Interventional Cardiology, Sandro Pertini Hospital, 00157 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nardi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Santo Spirito Hospital, 15033 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3392-0527","authenticated-orcid":false,"given":"Domenico","family":"Gabrielli","sequence":"additional","affiliation":[{"name":"Department of Cardio-Thoracic and Vascular Medicine and Surgery, Division of Cardiology, S. Camillo-Forlanini Hospital, 00152 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-1959","authenticated-orcid":false,"given":"Carmine","family":"Savoia","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Medicine Department, Faculty of Medicine and Psychology, Sant\u2019Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-2234","authenticated-orcid":false,"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[{"name":"Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, 00135 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"key":"ref_1","unstructured":"Chugh, S.S. (2018). Epidemiology and global burden of hypertension. Epidemiology and Global Burden, the ESC Textbook of Cardiovascular Medicine, ESC Publications. [3rd ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1111\/bph.70063","article-title":"Advancing antihypertensive drug development","volume":"182","author":"Pu","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"ref_3","first-page":"sfae346","article-title":"Clinical implications of mineralocorticoid receptor overactivation","volume":"18","author":"Chhikara","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.59556\/japi.74.1293","article-title":"Mineralocorticoid Receptor Antagonists: An Overview of History and Evolution","volume":"74","author":"Kalmath","year":"2026","journal-title":"J. Assoc. Physicians India"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ji, K., Huang, X., Wang, F., Zhang, L., Zheng, Y., Ji, L., Ju, Y., Zhuang, X., and Li, J. (2026). Comparative safety profiles of spironolactone, eplerenone, and finerenone: A pharmacovigilance study based on FAERS data from 2004 to 2024. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1702257"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101386","DOI":"10.1016\/j.cpcardiol.2022.101386","article-title":"Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection","volume":"47","author":"Parfianowicz","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.13005\/bpj\/3217","article-title":"Mechanistic Understanding of Finerenone in Hypertension Management: A Narrative Review","volume":"18","author":"Prasad","year":"2025","journal-title":"Biomed. Pharmacol. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103194","DOI":"10.1016\/j.nepr.2021.103194","article-title":"PICO: What it is and what it is not","volume":"56","author":"Schiavenato","year":"2021","journal-title":"Nurse Educ. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa2512854","article-title":"Finerenone in Type 1 Diabetes and Chronic Kidney Disease","volume":"394","author":"Heerspink","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s12933-025-03014-x","article-title":"Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: A randomised placebo-controlled mechanistic trial (FIVE-STAR)","volume":"24","author":"Tanaka","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jamacardio.2026.2104","article-title":"Finerenone and Blood Pressure in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial","volume":"11","author":"Ostrominski","year":"2026","journal-title":"JAMA Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ostrominski, J.W., Claggett, B.L., Kulac, I.J., Desai, A.S., Jhund, P.S., Henderson, A., Lam, C.S.P., Senni, M., Shah, S.J., and Voors, A.A. (2026). Finerenone and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction. Eur. J. Heart Fail., xuag209.","DOI":"10.1093\/ejhf\/xuag209"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2337\/db24-878-P","article-title":"878-P: Effect of finerenone on resistant hypertension in type 2 diabetes mellitus\u2014A randomized controlled trial in Indian population","volume":"73","author":"Gadve","year":"2024","journal-title":"Diabetes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e26048","DOI":"10.1161\/HYPERTENSIONAHA.125.26048","article-title":"Efficacy and Safety of Finerenone in Patients with Primary Aldosteronism: A Multicenter Prospective Study","volume":"83","author":"Li","year":"2026","journal-title":"Hypertension"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e27036","DOI":"10.1161\/HYPERTENSIONAHA.126.27036","article-title":"Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure","volume":"83","author":"Agarwal","year":"2026","journal-title":"Hypertension"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7694\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:12:45Z","timestamp":1791198765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,4]]},"references-count":24,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197694"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197694","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,4]]}}}